Culver City-based ImmunityBio, Inc., a leading immunotherapy company, has announced that the U.S. Food and Drug ...
A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract ...
The US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...
Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...
Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...
Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...
BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1 ...
The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more ...
Read more at about DURIPANC at ClinicalTrials.gov NCT05927142 - "Combining anti-PD-L1 immune checkpoint inhibitor durvalumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback